The immune system does not fight cancer (no antibodies form against it), which shows the body accepts the tumour; therefore attacking it with chemotherapy is wrong.
Original statement
جسمك ما حاروش ليه وما عملش ليه ضده اجسام مضاده
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
The immune system does not fight cancer (no antibodies form against it), which shows the body accepts the tumour; therefore attacking it with chemotherapy is wrong.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr.D Clinics - Diaa Al Awady is live! (Open source)
- Published
- 16 March 2025
- Timestamp
- 0:14:27 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
- Population concerned
Cancer patients
- Geographic restriction by Elawady
none found
Diverging source versions
يقول لنا ليه السرطان ما بيطلعش ضده جسم مضاد
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! التراكمي عال و السكر واطيي (Open source)
- Published
- 5 October 2025
- Timestamp
- 0:37:43 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
No immune response to cancer; the body tolerates it on purpose.
2. What is demonstrably correct?
Tumours evade immune control (immune evasion is a recognised hallmark of cancer, I-CAN-122), and antibodies against tumour proteins do not by themselves eliminate tumours (I-CAN-121).
3. What is wrong or exaggerated?
The immune system does respond to cancer: about 30% of patients form antibodies against the tumour protein p53 (I-CAN-121); immune cells in colorectal tumours predict survival (I-CAN-120); people with weakened immunity have higher rates of 20 of 28 cancer types (I-CAN-119); and releasing immune checkpoints lets T cells control metastatic melanoma (5-year survival 52% vs 26%; I-CHM-08). Immune evasion is a mechanism of cancer, not a sign that the tumour is beneficial, and it is no argument against chemotherapy.
4. What remains unclear?
Why some cancers respond to immunotherapy and others do not is still being studied; the cited trial concerns metastatic melanoma (I-CHM-08).
5. Which studies support it?
Only for the kernel: tumours evade immune destruction (I-CAN-122). None for the conclusion.
6. Which studies contradict it?
I-CHM-08, I-CAN-119, I-CAN-120, I-CAN-121.
7. What applies to Germany and Europe?
Not region-specific; checkpoint immunotherapy is used in European oncology for several cancers (not audited in detail).
8. What is known about Egypt?
Not region-specific; access to immunotherapy in Egypt was not reviewed.
9. What practical conclusion is appropriate?
Immunotherapy is an option for some cancers, chosen by oncologists.
Assessment details
- Rationale for certainty of evidence
High: immune deficiency raises the incidence of many cancers (I-CAN-119), tumour-infiltrating immune cells predict survival (I-CAN-120), antibodies against tumour proteins are common (I-CAN-121), and an RCT shows that releasing immune checkpoints controls metastatic melanoma (I-CHM-08). The kernel that tumours evade immunity is real (I-CAN-122), which is why the verdict is “Mostly false” rather than “False”.
- Source quality
Machine transcripts.
- Regional transferability
High.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.
Research question: In humans, does the immune system recognise and act against cancer (e.g., antibodies, T-cell infiltration, immune surveillance), and does the absence of complete immune elimination imply that anticancer treatment is wrong?
Research question in detail (PECO)
- Population
- People with or at risk of cancer
- Intervention or exposure
- Immune responses to tumours; immune deficiency
- Comparison
- Immunocompetent / no immune response
- Geographic scope
- universal biology
- Outcomes
- Tumour-specific antibodies
- Immune infiltration and survival
- Cancer incidence under immunosuppression
- Response to immunotherapy
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Hallmarks of cancer
Hanahan D et al.. Cell 2011 · PMID 21376230 · DOI 10.1016/j.cell.2011.02.013 Narrative reviewabstract checkednewly addedHallmarks review: evading immune destruction is an acquired capability of cancers.
- Actual result
- Immune evasion listed as emerging hallmark
- Methodological quality
- moderate (consensus review)
- Relevance
- indirect: explains the kernel that tumours escape immunity
- Limitations
- Does not imply the body accepts the tumour on purpose.
What speaks against the claim?
Weakened immunity raises cancer risk
Grulich AE et al.. Lancet 2007 · PMID 17617273 · DOI 10.1016/S0140-6736(07)61050-2 Meta-analysisabstract checkednewly addedImmune-deficient people (HIV/AIDS, transplant recipients) have higher rates of many cancers.
- Actual result
- 20 of 28 cancer types increased; e.g. Hodgkin SIR 11.03 (HIV) and 3.89 (transplant)
- Methodological quality
- high (meta-analysis of population cohorts)
- Relevance
- direct for immune surveillance
- Limitations
- Mostly infection-related cancers; common epithelial cancers not increased.
Immunotherapy lets half of patients with advanced melanoma live at least five years
Larkin J et al.. N Engl J Med 2019 · PMID 31562797 · DOI 10.1056/NEJMoa1910836 Randomised controlled trialabstract checkedCheckpoint immunotherapy RCT in advanced melanoma.
- Actual result
- 5-year survival 52% vs 26%
- Methodological quality
- high (RCT)
- Relevance
- direct: releasing immune brakes controls cancer
- Limitations
- One cancer type.
Cancer patients do make antibodies against their tumours
Review of >130 studies on serum p53 antibodies.
- Actual result
- Antibodies in ~30% of patients, specificity 96%
- Methodological quality
- low-moderate (narrative)
- Relevance
- direct refutation of 'no antibodies form'
- Limitations
- Antibodies associated with poor prognosis, i.e. not protective.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
The immune system does recognise and act against cancer; tumours progress partly because they evolve ways to evade it. Immune evasion does not show that the body 'accepts' the tumour, and it is no argument against chemotherapy, whose efficacy is shown in RCTs.
Why some studies weigh more
Population data on immune deficiency (I-CAN-119) and the RCT of checkpoint inhibition (I-CHM-08) weigh most; prognostic and antibody studies (I-CAN-120, I-CAN-121) directly contradict the factual premise.
Is a causal relationship established? Yes, established Immunosuppression increases cancer incidence in two independent populations, and restoring T-cell activity controls cancer in RCTs.
Remaining uncertainty
Which cancers are under effective immune control varies by type.
Justified conclusion
The premise is false (antibodies and T-cell responses occur), and the conclusion against treatment does not follow.
Why do studies seem to disagree?
No real conflict: the observation that immunity often fails to eliminate tumours (I-CAN-122, I-CAN-121 poor prognosis) and the evidence that immunity acts against tumours (I-CAN-119, I-CAN-120, I-CHM-08) describe two sides of the same tumour-immune interaction.
Does this depend on the country?
- General biological effects
- Universal human biology; applies in Egypt, Germany and elsewhere.
- Eating habits
- Not decisive for this claim.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant.
- National production conditions
- Not relevant.
- Legal rules
- Not relevant.
- Actual monitoring data
- Not applicable.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- CI log-symmetry of SIRs – All six SIR CIs symmetric on the log scale. recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Immune control of cancer in humans
- Starting level
- low (observational studies)
- Reasons for upgrading
- large effect (SIRs up to 11)
- consistency across two immune-deficient populations and RCT evidence
- Result
- high
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | (cancer OR malignancy) AND ("transplant recipients" OR "HIV/AIDS" OR immunosuppression) AND (incidence) AND (meta-analysis) AND TITLE:(cancer OR cancers) | contradicting evidence | 4586 | |
| Europe PMC | 26 October 2026 | TITLE:"Hallmarks of Cancer: New Dimensions" | supporting evidence | 1 | |
| Europe PMC | 26 October 2026 | ("tumor-infiltrating lymphocytes" OR "tumour-infiltrating lymphocytes" OR "immunoscore") AND (survival OR prognosis) AND (meta-analysis) AND TITLE:(lymphocytes OR immunoscore) | contradicting evidence | 411 | |
| Europe PMC | 26 October 2026 | TITLE:"Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients" | contradicting evidence | 1 | |
| Europe PMC | 26 October 2026 | TITLE:"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome" | contradicting evidence | 1 | |
| Europe PMC | 26 October 2026 | ("p53 antibodies" OR "tumor-associated autoantibodies" OR "tumour-associated antigens autoantibodies") AND (sera OR serum) AND (cancer patients) AND (review OR meta-analysis) | contradicting evidence | 726 | |
| Europe PMC | 26 October 2026 | (Tayebat OR Tayibat OR Elawady OR "El-Awady diet" OR "Al-Awady") | both directions | 377 | |
| PubMed | 26 October 2026 | ("immune evasion"[tiab] OR "immune escape"[tiab] OR "immune tolerance"[tiab]) AND (tumor[tiab] OR cancer[tiab]) AND review[pt] | supporting evidence | 9246 | |
| PubMed | 26 October 2026 | ("immunosurveillance"[tiab] OR "immune surveillance"[tiab]) AND cancer[tiab] AND (transplant[tiab] OR immunosuppression[tiab]) AND (meta-analysis[pt] OR cohort[tiab]) | contradicting evidence | 24 |
Open questions
Why immune control works for some cancer types and not others.
How deeply was this checked?
5 linked studies: 0 checked in full text (0 of them with a structured risk-of-bias assessment), 5 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Mostly false (moderate)
- 26 October 2026 · Phase 4 (systematic evidence review) · Verdict changed: Mostly false (moderate) → Mostly false (high)
Certainty raised from moderate to high: the factual premise ('no antibodies form', 'the immune system does not fight cancer') is now directly contradicted by population data on immune deficiency (I-CAN-119), immune-infiltrate prognosis (I-CAN-120) and tumour antibodies (I-CAN-121), in addition to the RCT (I-CHM-08). Verdict stays “Mostly false” because the kernel (immune evasion) is real.
New sources: I-CAN-119 I-CAN-120 I-CAN-121 I-CAN-122
In plain language
Dr. Diaa argued that the body does not fight cancer and makes no antibodies against it, so it 'wants' the tumour. In fact, many patients make antibodies against tumour proteins, immune cells inside tumours are linked to longer survival, and people with weak immune systems get certain cancers more often. Cancers grow partly because they learn to hide from the immune system. Modern drugs that remove these 'brakes' let the immune system attack the cancer.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (4)
-
Immunotherapy lets half of patients with advanced melanoma live at least five years
Larkin J et al.. N Engl J Med 2019 · PMID 31562797 · DOI 10.1056/NEJMoa1910836Randomised controlled trialindependent cross-checkabstract checked5-year survival 52% with combined immunotherapy vs 26% with the older drug.
T cells can control cancer
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Report 5-year survival.
- How was the study done?
RCT.
- How many people, animals or samples were studied?
Advanced melanoma.
- What was actually found?
52% 5-year OS.
- How large was the observed effect?
HR 0.52.
- What do the results mean in everyday life?
The immune system can fight cancer when helped.
- What are the study's limitations?
Industry funding.
- What does it say about Elawady's specific claim?
Contradicts immune claim.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Effect in other cancers.
-
Weakened immunity raises cancer risk
Grulich AE et al.. Lancet 2007 · PMID 17617273 · DOI 10.1016/S0140-6736(07)61050-2Meta-analysisindependent cross-checkabstract checked★ key studyPeople with HIV/AIDS or on transplant drugs had higher rates of 20 of 28 cancer types.
Immune deficiency raises incidence of 20 of 28 cancer types
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare cancer in two immune-deficient groups.
- How was the study done?
Meta-analysis of cohorts.
- How many people, animals or samples were studied?
~476,000 people.
- What was actually found?
Many cancers more frequent.
- How large was the observed effect?
e.g. Hodgkin SIR 11.03.
- What do the results mean in everyday life?
The immune system helps keep cancer in check.
- What are the study's limitations?
Mainly infection-related cancers.
- What does it say about Elawady's specific claim?
Contradicts the claim.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Immune control of every cancer type.
-
Immune cells inside bowel tumours predict survival
Galon J et al.. Science 2006 · PMID 17008531 · DOI 10.1126/science.1129139Cohort studyindependent cross-checkabstract checkedPatients whose tumours contained more of certain immune cells survived longer.
Immune infiltration predicts survival
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Link tumour immune cells and survival.
- How was the study done?
Cohorts with validation.
- How many people, animals or samples were studied?
Colorectal cancer patients.
- What was actually found?
Immune data predicted survival better than staging.
- How large was the observed effect?
Not given in abstract.
- What do the results mean in everyday life?
The body's immune system fights cancer to some degree.
- What are the study's limitations?
Association.
- What does it say about Elawady's specific claim?
Contradicts the claim.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Causation alone.
-
Cancer patients do make antibodies against their tumours
Soussi T. Cancer Res 2000 · PMID 10766157Narrative reviewindependent cross-checkabstract checkedAbout 30% of cancer patients have antibodies against the tumour protein p53.
Antibodies against tumour proteins form in ~30% of patients
Does the study support the specific claim? No · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Review p53 antibodies.
- How was the study done?
Narrative review.
- How many people, animals or samples were studied?
>130 studies.
- What was actually found?
Antibodies common in cancer patients.
- How large was the observed effect?
Specificity 96%, sensitivity 30%.
- What do the results mean in everyday life?
The immune system notices cancer, though it may not stop it.
- What are the study's limitations?
Older narrative review.
- What does it say about Elawady's specific claim?
Refutes 'no antibodies form'.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That antibodies control tumours.
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
Hallmarks of cancer
Hanahan D et al.. Cell 2011 · PMID 21376230 · DOI 10.1016/j.cell.2011.02.013Narrative reviewindependent cross-checkabstract checkedCancers acquire the ability to escape immune destruction; this is why they can grow despite immunity.
Immune evasion is real (kernel) but is an acquired cancer capability
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Define cancer capabilities.
- How was the study done?
Review.
- How many people, animals or samples were studied?
Not applicable.
- What was actually found?
Immune evasion is a hallmark.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
Tumours hide from immunity; this is a disease feature.
- What are the study's limitations?
Conceptual.
- What does it say about Elawady's specific claim?
Partly explains Elawady's observation, not his conclusion.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Any purpose of cancer.
No study in this group is marked as key.
Regional context
Germany / EU
Not region-specific; checkpoint immunotherapy is used in European oncology for several cancers (not audited in detail).
Egypt
Not region-specific; access to immunotherapy in Egypt was not reviewed.
What applies in my country?
General scientific assessment
Mostly false The immune system does act against cancer; tumours grow partly because they evade it, which is not proof that the body wants the tumour and no reason to refuse treatment.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.. Larkin J et al.. N Engl J Med 2019 · PMID 31562797 · DOI 10.1056/NEJMoa1910836
- Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.. Grulich AE et al.. Lancet 2007 · PMID 17617273 · DOI 10.1016/S0140-6736(07)61050-2
- Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.. Galon J et al.. Science 2006 · PMID 17008531 · DOI 10.1126/science.1129139
- p53 Antibodies in the sera of patients with various types of cancer: a review.. Soussi T. Cancer Res 2000 · PMID 10766157
- Hallmarks of cancer: the next generation.. Hanahan D et al.. Cell 2011 · PMID 21376230 · DOI 10.1016/j.cell.2011.02.013